stoxline Quote Chart Rank Option Currency Glossary
  
Entera Bio Ltd. (ENTX)
1.67  0.13 (8.44%)    03-28 16:00
Open: 1.6
High: 1.75
Volume: 124,441
  
Pre. Close: 1.54
Low: 1.54
Market Cap: 59(M)
Technical analysis
2024-03-28 4:51:07 PM
Short term     
Mid term     
Targets 6-month :  2.18 1-year :  2.55
Resists First :  1.87 Second :  2.18
Pivot price 1.49
Supports First :  1.33 Second :  1
MAs MA(5) :  1.57 MA(20) :  1.49
MA(100) :  0.93 MA(250) :  0.84
MACD MACD :  0.1 Signal :  0.1
%K %D K(14,3) :  60.9 D(3) :  53.4
RSI RSI(14): 64.5
52-week High :  1.87 Low :  0.51
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ ENTX ] has closed below upper band by 8.5%. Bollinger Bands are 22.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.75 - 1.77 1.77 - 1.78
Low: 1.51 - 1.53 1.53 - 1.54
Close: 1.65 - 1.67 1.67 - 1.69
Company Description

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

Headline News

Tue, 26 Mar 2024
Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on ... - TradingView

Mon, 25 Mar 2024
OPKO Health (OPK) And Entera Bio Announce Data for GLP-2 - Yahoo Finance

Sat, 23 Mar 2024
Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation - Simply Wall St

Wed, 20 Mar 2024
Should Biotechnology Stock Entera Bio Ltd (ENTX) Be in Your Portfolio Wednesday? - InvestorsObserver

Fri, 08 Mar 2024
Entera Bio Ltd Shares Financial Update for Investor Awareness - TipRanks.com - TipRanks

Fri, 08 Mar 2024
Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 35 (M)
Shares Float 25 (M)
Held by Insiders 19.1 (%)
Held by Institutions 11.4 (%)
Shares Short 1 (K)
Shares Short P.Month 3 (K)
Stock Financials
EPS -0.32
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.28
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -44.7 %
Return on Equity (ttm) -80.4 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.25
Qtrly Earnings Growth 0 %
Operating Cash Flow -7 (M)
Levered Free Cash Flow -4 (M)
Stock Valuations
PE Ratio -5.39
PEG Ratio 0
Price to Book value 5.75
Price to Sales 0
Price to Cash Flow -8.11
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android